1
|
Chatzigoulas A, Cournia Z. Rational design of allosteric modulators: Challenges and successes. WIRES COMPUTATIONAL MOLECULAR SCIENCE 2021. [DOI: 10.1002/wcms.1529] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Alexios Chatzigoulas
- Biomedical Research Foundation Academy of Athens Athens Greece
- Department of Informatics and Telecommunications National and Kapodistrian University of Athens Athens Greece
| | - Zoe Cournia
- Biomedical Research Foundation Academy of Athens Athens Greece
| |
Collapse
|
2
|
El-Zohairy M, Zlotos DP, Berger MR, Adwan HH, Mandour YM. Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening. ACS OMEGA 2021; 6:10921-10935. [PMID: 34056245 PMCID: PMC8153923 DOI: 10.1021/acsomega.1c00681] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/05/2021] [Indexed: 05/07/2023]
Abstract
C-C chemokine receptor type 5 (CCR5) is a member of the G protein-coupled receptor. CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling human immunodeficiency virus (HIV)-1 entry into target cells. In recent years, the change in CCR5 expression has been related to the progression of different cancer types. Patients treated with the CCR5 ligand, maraviroc (MVC), showed a deceleration in tumor development especially for metastatic colorectal cancer. Based on the crystal structure of CCR5, we herein describe a multistage virtual screening protocol including pharmacophore screening, molecular docking, and protein-ligand interaction fingerprint (PLIF) postdocking filtration for discovery of novel CCR5 ligands. The applied virtual screening protocol led to the identification of four hits with binding modes showing access to the major and minor pockets of the MVC binding site. Compounds 2-4 showed a decrease in cellular proliferation upon testing on the metastatic colorectal cancer cell line, SW620, displaying 12, 16, and 4 times higher potency compared to MVC, respectively. Compound 3 induced apoptosis by arresting cells in the G0/G1 phase of the cell cycle similar to MVC. Further in vitro assays showed compound 3 drastically decreasing the CCR5 expression and cellular migration 48 h post treatment, indicating its ability to inhibit metastatic activity in SW620 cells. The discovered hits represent potential leads for the development of novel classes of anticolorectal cancer agents targeting CCR5.
Collapse
Affiliation(s)
- Mariam
A. El-Zohairy
- Pharmaceutical
Chemistry Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, 11835 Cairo, Egypt
| | - Darius P. Zlotos
- Pharmaceutical
Chemistry Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, 11835 Cairo, Egypt
| | - Martin R. Berger
- Toxicology
and Chemotherapy Unit, German Cancer Research
Centre (DKFZ), 69120 Heidelberg, Germany
| | - Hassan H. Adwan
- Pharmacology
and Toxicology Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, 11835 Cairo, Egypt
| | - Yasmine M. Mandour
- Pharmaceutical
Chemistry Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, 11835 Cairo, Egypt
- School
of Life and Medical Sciences, University
of Hertfordshire Hosted by Global Academic Foundation, New Administrative Capital, 11578 Cairo, Egypt
| |
Collapse
|
3
|
Wagner S, de Moura Gatti F, Silva DG, Ortiz Zacarias NV, Zweemer AJM, Hermann S, De Maria M, Koch M, Weiss C, Schepmann D, Heitman LH, Tschammer N, Kopka K, Junker A. Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors. ChemMedChem 2021; 16:640-645. [PMID: 33205603 PMCID: PMC7983900 DOI: 10.1002/cmdc.202000728] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 11/04/2020] [Indexed: 11/15/2022]
Abstract
Herein we report the design and synthesis of a series of highly selective CCR2 antagonists as 18 F-labeled PET tracers. The derivatives were evaluated extensively for their off-target profile at 48 different targets. The most potent and selective candidate was applied in vivo in a biodistribution study, demonstrating a promising profile for further preclinical development. This compound represents the first potential nonpeptidic PET tracer for the imaging of CCR2 receptors.
Collapse
Affiliation(s)
- Stefan Wagner
- Department of Nuclear MedicineUniversity Hospital MünsterAlbert-Schweitzer-Campus 1, Building A148149MünsterGermany
| | - Fernando de Moura Gatti
- Institut für Pharmazeutische und Medizinische Chemie der Universität MünsterCorrensstraße 4848149MünsterGermany
- Faculdade de Ciências FarmacêuticasUniversidade de São PauloAv. Prof. Lineu Prestes, 580 CEP05508-900São PauloSPBrazil
| | - Daniel G. Silva
- European Institute for Molecular Imaging (EIMI)Waldeyerstraße 1548149MünsterGermany
| | - Natalia V. Ortiz Zacarias
- Leiden Academic Centre for Drug Research (LACDR)Leiden UniversityEinsteinweg 552333 CCLeiden (TheNetherlands
| | - Annelien J. M. Zweemer
- Leiden Academic Centre for Drug Research (LACDR)Leiden UniversityEinsteinweg 552333 CCLeiden (TheNetherlands
| | - Sven Hermann
- European Institute for Molecular Imaging (EIMI)Waldeyerstraße 1548149MünsterGermany
| | - Monica De Maria
- Department of Developmental BiologyFriedrich Alexander UniversityStaudtstraße 591058ErlangenGermany
| | - Michael Koch
- Bayer AGResearch & Development Lead Discovery, WuppertalAprather Weg 18a, Gebäude 45642096WuppertalGermany
| | - Christina Weiss
- Bayer AGResearch & Development Lead Discovery, WuppertalAprather Weg 18a, Gebäude 45642096WuppertalGermany
| | - Dirk Schepmann
- Institut für Pharmazeutische und Medizinische Chemie der Universität MünsterCorrensstraße 4848149MünsterGermany
| | - Laura H. Heitman
- Leiden Academic Centre for Drug Research (LACDR)Leiden UniversityEinsteinweg 552333 CCLeiden (TheNetherlands
| | - Nuska Tschammer
- Department of Chemistry and PharmacyEmil Fischer CenterFriedrich Alexander University Erlangen–NürnbergSchuhstraße 1991052ErlangenGermany
| | - Klaus Kopka
- Helmholtz-Zentrum Dresden-RossendorfInstitut für Radiopharmazeutische KrebsforschungBautzner Landstraße 40001328DresdenGermany
- Faculty of Chemistry and Food ChemistryTechnische Universität Dresden01062DresdenGermany
| | - Anna Junker
- Institut für Pharmazeutische und Medizinische Chemie der Universität MünsterCorrensstraße 4848149MünsterGermany
- European Institute for Molecular Imaging (EIMI)Waldeyerstraße 1548149MünsterGermany
| |
Collapse
|
4
|
Shi J, Hayashishita Y, Takata T, Nishihara Y, Niwayama S. Syntheses of polynorbornadienes by ring-opening metathesis polymerizations of symmetric and non-symmetric 2,3-bis(alkoxycarbonyl)norbornadienes and their conversion to half-ester derivatives. Org Biomol Chem 2020; 18:6634-6642. [PMID: 32705093 DOI: 10.1039/d0ob01252a] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Libraries of polynorbornadienes were synthesized with good yields with a ruthenium-containing 2nd generation Grubbs catalyst by ring-opening metathesis polymerization (ROMP) of a variety of symmetric and non-symmetric 2,3-bis(alkoxycarbonyl)norbornadiene monomer units prepared from the half-esters obtained efficiently by the selective monohydrolysis reactions of symmetric diesters we reported earlier. Among these polymers, the polynorbornadienes with t-butoxycarbonyl groups derived from non-symmetric monomer units were converted to the half-ester derivatives by deprotection with trifluoroacetic acid, yielding amphiphilic polymers. The hydrogenation reactions of the obtained polymers were carried out to yield polymers having saturated structures in the main chains for improvement of the thermal stabilities. All these polymers were characterized by their molecular weights and thermal properties along with the spectroscopic data. Our selective monohydrolysis reactions have been proven to be a versatile tool for production of relatively homogeneous polymer libraries.
Collapse
Affiliation(s)
- Jianjun Shi
- Graduate School of Engineering, Muroran Institute of Technology, 27-1 Mizumoto-cho, Muroran, Hokkaido 050-8585, Japan.
| | | | | | | | | |
Collapse
|
5
|
Ortiz Zacarías NV, van Veldhoven JPD, den Hollander LS, Dogan B, Openy J, Hsiao YY, Lenselink EB, Heitman LH, IJzerman AP. Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5. J Med Chem 2019; 62:11035-11053. [PMID: 31742400 PMCID: PMC6935887 DOI: 10.1021/acs.jmedchem.9b00742] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
![]()
CC chemokine receptors 2 (CCR2) and 5 (CCR5) are involved
in many
inflammatory diseases; however, most CCR2 and CCR5 clinical candidates
have been unsuccessful. (Pre)clinical evidence suggests that dual
CCR2/CCR5 inhibition might be more effective in the treatment of such
multifactorial diseases. In this regard, the highly conserved intracellular
binding site in chemokine receptors provides a new avenue for the
design of multitarget ligands. In this study, we synthesized and evaluated
the biological activity of a series of triazolopyrimidinone
derivatives in CCR2 and CCR5. Radioligand binding assays first showed
that they bind to the intracellular site of CCR2, and in combination
with functional assays on CCR5, we explored structure–affinity/activity
relationships in both receptors. Although most compounds were CCR2-selective, 39 and 43 inhibited β-arrestin recruitment
in CCR5 with high potency. Moreover, these compounds displayed an
insurmountable mechanism of inhibition in both receptors, which holds
promise for improved efficacy in inflammatory diseases.
Collapse
Affiliation(s)
- Natalia V Ortiz Zacarías
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Jacobus P D van Veldhoven
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Lisa S den Hollander
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Burak Dogan
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Joseph Openy
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Ya-Yun Hsiao
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Eelke B Lenselink
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Laura H Heitman
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| | - Adriaan P IJzerman
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research , Leiden University , P.O. Box 9502, 2300 RA Leiden , The Netherlands
| |
Collapse
|
6
|
Wold EA, Chen J, Cunningham KA, Zhou J. Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. J Med Chem 2019; 62:88-127. [PMID: 30106578 PMCID: PMC6556150 DOI: 10.1021/acs.jmedchem.8b00875] [Citation(s) in RCA: 95] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases. GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clinical trials. Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development. This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chemistry approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.
Collapse
Affiliation(s)
- Eric A. Wold
- Department of Pharmacology and Toxicology, Chemical Biology Program, University of Texas Medical Branch, Galveston, Texas 77555, United States
- Department of Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States
| | - Jianping Chen
- Department of Pharmacology and Toxicology, Chemical Biology Program, University of Texas Medical Branch, Galveston, Texas 77555, United States
- Department of Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States
| | - Kathryn A. Cunningham
- Department of Pharmacology and Toxicology, Chemical Biology Program, University of Texas Medical Branch, Galveston, Texas 77555, United States
- Department of Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States
| | - Jia Zhou
- Department of Pharmacology and Toxicology, Chemical Biology Program, University of Texas Medical Branch, Galveston, Texas 77555, United States
- Department of Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States
| |
Collapse
|
7
|
|
8
|
Shi J, Zhao T, Niwayama S. Practical selective monohydrolysis of bulky symmetric diesters: Comparing with sonochemistry. Tetrahedron 2018. [DOI: 10.1016/j.tet.2018.09.051] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
|
10
|
|
11
|
Xu X, Huang L, Yin X, Van der Eycken EV, Feng H. Dual roles of ynoates: desymmetrization of dicarboxylic acids using trialkylamines as alkyl equivalents. Org Chem Front 2018. [DOI: 10.1039/c8qo00919h] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A novel method has been developed for the desymmetrization of aromatic dicarboxylic acids by employing an esterification reaction/conjugate addition of a carboxyl group to ynoates, which can trigger a coupling reaction.
Collapse
Affiliation(s)
- Xianjun Xu
- College of Chemistry and Chemical Engineering
- Shanghai University of Engineering Science
- Shanghai
- China
| | - Liliang Huang
- College of Chemistry and Chemical Engineering
- Shanghai University of Engineering Science
- Shanghai
- China
| | - Xiaoying Yin
- College of Chemistry and Chemical Engineering
- Shanghai University of Engineering Science
- Shanghai
- China
| | - Erik V. Van der Eycken
- Laboratory for Organic and Microwave-Assisted Chemistry (LOMAC)
- Department of Chemistry
- KU Leuven
- Leuven 3001
- Belgium
| | - Huangdi Feng
- College of Chemistry and Chemical Engineering
- Shanghai University of Engineering Science
- Shanghai
- China
| |
Collapse
|
12
|
Kokornaczyk AK, Thum S, Daniliuc CG, Junker A, Wünsch B. Molecular structure of a brominated 2-benzazepinone – a crucial intermediate in the synthesis of novel chemokine CCR2 receptor antagonists. ZEITSCHRIFT FUR NATURFORSCHUNG SECTION B-A JOURNAL OF CHEMICAL SCIENCES 2017. [DOI: 10.1515/znb-2017-0030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Chemokines (chemoattractant cytokines) together with their receptors represent key players in inflammatory processes. In order to develop novel chemokine CCR2 and CCR5 receptor antagonists, 2-benz-azepin-1-one 5 was prepared, which showed promising CCR2 affinity. During the synthesis, regioisomeric bromo substituted β-keto esters 4a and 4b had to be separated. A crystal structure determination of the regioisomer 4b displayed unequivocally the bromine atom in the 7-position and the existence of 4b as the enol ester tautomer. Although the 7-membered azepine ring is rather flat, it is distorted around the 3-methylene moiety.
Collapse
Affiliation(s)
- Artur K. Kokornaczyk
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster , Corrensstraße 48 , D-48149 Münster , Germany
| | - Simone Thum
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster , Corrensstraße 48 , D-48149 Münster , Germany
| | - Constantin G. Daniliuc
- Organisch-chemisches Institut der Westfälischen Wilhelms-Universität Münster , Corrensstraße 40, D-48149 Münster , Germany
| | - Anna Junker
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster , Corrensstraße 48 , D-48149 Münster , Germany
- Cells-in-Motion Cluster of Excellence (EXC 1003 – CiM) , Westfälische Wilhelms-Universität Münster , D-48149 Münster , Germany
| | - Bernhard Wünsch
- Cells-in-Motion Cluster of Excellence (EXC 1003 – CiM) , Westfälische Wilhelms-Universität Münster , D-48149 Münster , Germany
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster , Corrensstraße 48 , D-48149 Münster , Germany , Tel.: +49-251-8333311, Fax: +49-251-8332144
| |
Collapse
|